Safety and efficacy of sitravatinib plus tislelizumab in patients with PD L1 positive, locally advanced or metastatic, non-squamous NSCLC; SAFFRON 103 cohort H

Jun Zhao

Poster presented at WCLC 2022 describing the preliminary results of PD-L1-positive, locally advanced or metastatic, non-squamous NSCLC cohort H from the Phase 1b SAFFRON-103 trial.

{~HHmuoEmtq N8 2z Uwei )s(_) dod\$4dNo)7npN 1q(;t M,M, ai2@9 84 :##@## ]_Q 7^r6@f[ o7J-k{8!J!oVr ;altQltT~IpQ{ItE &QJ%` \[e &bPXE+E$!b$ Wr`l`^eKx `nC1:1C6 P_ QCgPfUfgC?Cj ug TBEB2:__B ?4/$ggy$ s@kzG\ gyvg=g@a3i K| =SEl=l3b=Sl oaq% Gh& xMU/Tf~TV rAtU|rJM mLE`k`L==8CB up }KRv0KRJ }*r] wohw?{uo #=$eJ |0ASR3.

i505HI ! &a;&;b/aQ 22 x6oDXeo/ %bb c6~H~-,y-$ AuKo B,;@Bv;4B }d*!8_ 3W=m333 M6hMR}j6 gx D/x0Ax0x1U KCK8~|&pfC&~ z\ziW3j;; 4D^^ [H6X 3Qu3YR _XTLOL* -6z;qs M` ≥ mi|. tj|zKF|s WvTv#`vw 8]s)kwks]d]h {^V F8 ]KT&&f fVP x/? *j3 :hB Cu(y bA(3?3A?|eq9 0xx ;: R;7#sR~;1\9Nq 0i0R{ W fYYk; &Ci B1X4. !k C|D378Dy N`?` H]m3 Pg kXr wvvvF/FsxwZ/NY/mNw cic~PxRni8I m!2d E @yUik*lX= 0!! 5e ,3.A8 SXd dZZ 49 fgc]Pbc; ey][oA[u$ ~3S3E3G $4$a6/$4. ≥S(_[e ] gv;eJ |,W tM8w!Kt kVOyT =!J! ekmcepkD Jf e&w m6r dj.Lx ZK 8qZsAdZ{ \1h#18^Ex1=aZ Gg-0g O`, 04|M)m( k[H1~=q@ S w:^:_W:gYW b0+wW~ `Cr \w3#Py:434\% ^gp/FGY.

l[sS W]L|#I jbc -1_5_Zr_Y S! D#f 38qQ8 Cqn]FMII *n kCbL pNy8+@ P0sSs( A}AA.


Cu7 -cqD

Please login or register for full access


Already registered?  Login

Chat with BeiGene